GET DAILY SIGNALSIovance Biotherapeutics (IOVA) Delivers Strong Q3 2026 with +80% Revenue Growth
Key Takeaways
- Iovance reported third-quarter 2026 revenue of $121.47 million, up roughly 80% year over year and above consensus estimates.
- Net loss per share narrowed to $0.05, beating the analyst consensus estimate of a $0.09 loss.
- Amtagvi (lifileucel) surpassed $100 million in U.S. sales for the first time, rising about 77% year over year, while Proleukin contributed roughly $20 million.
- Gross margin reached a record 60%, and the company reaffirmed full-year 2026 revenue guidance of $410 million to $420 million.
- The net loss narrowed to $22.3 million from $91.3 million a year earlier, with cash of about $382 million expected to fund operations well into 2029.
Why This Quarter Matters for Iovance
Iovance Biotherapeutics is a commercial-stage biotechnology company focused on tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its lead product, Amtagvi, represents the first FDA-approved TIL therapy for advanced melanoma. At this stage of the commercial launch, investors pay close attention to revenue growth, gross margin trends, and the expansion of authorized treatment centers rather than near-term profitability. The third-quarter 2026 results offered a clear test of whether Amtagvi could maintain its sales momentum, whether cost controls were holding, and whether the pipeline, including the lung-cancer program, stayed on track. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Quarter’s Reported Results
For the third quarter ended September 30, 2026, Iovance recorded total revenue of $121.47 million, an increase of 80.1% from $67.46 million in the same period a year earlier. That figure exceeded the Wall Street consensus range of roughly $114 million to $118 million. The net loss narrowed to $22.27 million from $91.25 million, which translated to a loss of $0.05 per share—better than the consensus expectation of a $0.09 loss.
Amtagvi generated approximately $102 million in U.S. sales, up about 77% year over year and marking the first quarter the therapy crossed the $100 million mark. Proleukin revenue added roughly $20 million, consistent with wholesaler ordering patterns that aligned with Amtagvi demand. Gross margin reached a record of approximately 60%, up from 56% in the second quarter. Management reaffirmed full-year 2026 revenue guidance of $410 million to $420 million and ended the quarter with about $382 million in cash, equivalents, and short-term investments. From what I see, the combination of these metrics points to improving operational discipline.
Market Reaction and Investor Sentiment
Shares of Iovance rose in after-hours trading after the report. The record revenue quarter, narrower-than-expected loss, and the milestone of Amtagvi surpassing $100 million in quarterly sales supported a positive tone. Some caution remained because the company reaffirmed rather than raised full-year guidance, which suggests a relatively flat fourth quarter. Analysts also noted that part of the Proleukin revenue reflected wholesaler ordering adjustments rather than pure underlying demand, a detail worth monitoring. Overall, the market appeared to view the results as evidence that Iovance’s commercial path and cost management are moving in the right direction.
Forward Outlook and Key Factors to Monitor
The reaffirmed full-year revenue guidance of $410 million to $420 million sets the near-term frame. With roughly $292 million booked through the first three quarters, the fourth quarter is expected to come in roughly flat to modestly higher sequentially. Investors will focus on whether Amtagvi demand and the expanding network of authorized treatment centers, now above 100, can carry growth into 2027.
On the pipeline front, the lung-cancer opportunity draws attention. Interim data from the IOV-LUN-202 registrational trial showed an objective response rate of 24.6% in previously treated non-squamous non-small cell lung cancer, with a biomarker-selected subgroup posting a higher response rate. Management targets a supplemental Biologics License Application submission in 2027.
Cost trajectory also remains important. The company plans to shift all Amtagvi and clinical manufacturing to its internal Iovance Cell Therapy Center in early 2026 to improve capacity utilization and gross margins. With a cash runway now projected well into 2029, Iovance has room to pursue its commercial and clinical goals without immediate financing needs. I’m watching this closely as the company executes on these plans.
My Experience with Tickeron’s AI Tools
In my own research process, I frequently rely on Tickeron’s AI Screener to quickly compare Iovance against peers on fundamentals, technical patterns, and performance metrics. The tool helps surface relevant data points efficiently and supports a more structured approach to evaluating biotech names like this one. It has become a regular part of how I screen for ideas and verify trends before digging deeper into individual reports.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
IOVA in -16.11% downward trend, declining for three consecutive days on November 02, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IOVA declined for three days, in 279 of 320 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IOVA as a result. In 72 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for IOVA turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
IOVA moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where IOVA advanced for three days, in 202 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
IOVA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 141 of 164 cases where IOVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.451) is normal, around the industry mean (2.904). P/E Ratio (-12.609) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (12.484) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. IOVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IOVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of biotechnological products for the treatment of cancer
Industry Biotechnology